AstraZeneca PLC
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca Core R&D expense: -$13,822M in FY2025, up 13.2% from a year earlier.
Latest, FY2025
-13,822
Period ended Dec 31, 2025
Change on a year earlier
+13.2%
-12,211 in FY2024
History
6 years
Since FY2020
Sources
6
Documents cited below
Where the FY2025 figure comes from
“|| R&D expense | (14,232) | 171 | 236 | 3 | (13,822) | 13 | 12”
Source: Form 6-K FY2025Q4 Earnings Release ↗
Reported in Form 6-K Quarterly & Form 20-F Reported-to-Core Reconciliation.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Core R&D expense ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | -13,822 | +13.2% | Form 6-K FY2025Q4 Earnings Release ↗ |
| FY2024 | Dec 31, 2024 | -12,211 | +18.9% | Form 6-K FY2024Q4 Earnings Release ↗ |
| FY2023 | Dec 31, 2023 | -10,267 | +8.1% | Form 6-K FY2023Q4 Earnings Release ↗ |
| FY2022 | Dec 31, 2022 | -9,500 | +18.9% | Form 6-K FY2022Q4 Earnings Release ↗ |
| FY2021 | Dec 31, 2021 | -7,987 | +36.0% | Form 6-K FY2021Q4 Earnings Release ↗ |
| FY2020 | Dec 31, 2020 | -5,872 | – | Form 6-K FY2020Q4 Earnings Release ↗ |
Breakdown
What makes up core R&D expense
Cite this data
StockData. (2026). AstraZeneca Core R&D expense ($M), annual FY2020–FY2025 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/core-rd
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.